INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc.

Rafael Holdings fell $0.71 per share, or 34.98%, to $1.32 on September 30, 2026, after its Cyclo Therapeutics subsidiary reported that the Phase 3 TransportNPC study of Trappsol Cyclo did not achieve statistical significance on its primary endpoint. Pomerantz LLP is investigating whether Rafael and certain officers or directors engaged in securities fraud or other unlawful business practices; the allegations are under investigation.

Analysis

The incremental signal is legal overhang, not a new read-through on the drug: a plaintiff-firm investigation is not evidence of misconduct and does not establish that a claim will be filed or succeed. The core valuation risk remains whether the failed primary endpoint leaves any credible regulatory or commercial path for Cyclo Therapeutics’ asset. For Rafael Holdings, verify how much value and liquidity are actually exposed to that subsidiary before translating trial disappointment into a consolidated valuation or financing thesis.

Near term, the investigation may weigh on sentiment and increase volatility, but after the sharp trial-related repricing, this headline alone is a weak basis for a fresh short; borrow, liquidity, and any already-discounted legal risk matter. Over 1–3 months, the more consequential catalysts are management’s account of secondary endpoints, regulator feedback, any additional analysis or development plan, and disclosure of cash needs and subsidiary funding obligations. Over 6–18 months, a credible path to further development could preserve residual option value; absent that, asset impairment or financing pressure could make the clinical setback more consequential for RFL than the lawsuit itself. The contrarian risk is treating a failed primary endpoint as either automatic total asset loss or, conversely, assuming a rare-disease designation rescues the program without supporting evidence. Thesis weakens if credible regulator engagement and a funded development plan emerge; it strengthens if the company discontinues the program, records a material impairment, or discloses constrained liquidity.

Key Decisions for Investors

• Do not initiate a short solely on the investigation announcement. Treat it as a volatility and governance watch item; confirm whether a complaint is filed and whether it adds allegations beyond the publicly disclosed trial result.
• Keep RFL on a catalyst watchlist rather than adding on perceived cheapness. Before considering a long, verify subsidiary ownership and economics, consolidated cash and obligations, and the company’s stated next clinical/regulatory step.
• For existing exposure, size risk around the possibility that the asset’s residual value is substantially lower than hoped. Reassess promptly on a program discontinuation, impairment disclosure, or evidence that Rafael must fund further development; a regulator-supported path with transparent financing would falsify the most bearish case.